Navigation Links
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Date:11/13/2011

rimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently being studied in an interferon-free, Phase 3 program (FISSION and POSITRON) and in five Phase 2b trials in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 865-0693 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Webcast an Investor Event from the AASLD Meeting
2. Pharmasset to Present at Four Upcoming Investor Conferences
3. Pharmasset to Present at Canaccord Adams Conference
4. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
7. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
8. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
11. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- An analysis by Replikins, Ltd. of Pubmed data ... virus strains has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... Presented at 21st North American Cystic Fibrosis ... Findings in Adult population -, SOUTH PLAINFIELD, ... Inc.,(PTC), a biopharmaceutical company focused on the discovery, ... today announced encouraging data,from a Phase 2 clinical ...
... RIDGE, N.J., Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin ... acquiring, developing and,commercializing targeted cancer therapeutics, announced today ... Thursday, October 11, 2007 at 2:00 p.m.,Pacific Time ... Room in San Francisco.,Daniel Greenleaf, VioQuest,s president and ...
... SOMERSET, N.J., Oct. 5 Alfacell Corporation,(Nasdaq: ACEL ... call and,Webcast at 11 a.m. EDT on Monday, Oct. ... executive officer, and Lawrence A. Kenyon,executive vice president, chief ... Alfacell,s financial performance for the fiscal,fourth quarter and year ...
Cached Biology Technology:PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 2PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 3PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 4PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 5VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast 2
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
(Date:8/27/2014)... Thousands of fishing traps are lost or abandoned each ... as derelict traps, which continue to catch fish, crabs, ... in losses to habitat, fisheries, and the watermen who ... to a newly published NOAA study. , The report, ... the first of its kind to examine the derelict ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... be a leading cause of the decline of coral reefs ... Georgia have found that extreme low temperatures affect certain corals ... potentially catastrophic consequences for coral ecosystems. Their findings appear in ... Biology . Lead author Dustin Kemp, a postdoctoral associate ...
Cached Biology News:'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Study: Severe low temperatures devastate coral reefs in Florida Keys 2Study: Severe low temperatures devastate coral reefs in Florida Keys 3
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: